# US 2009/0275502 A1 · Methods and compositions for enhancing developmental potential of oocytes and preimplantation embryos

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0275502 A1
- Document ID: US20090275502A1
- Status: Published application
- Kind: A1
- Application number: 11/917,675
- Filed: 2006-06-16
- Published: 2009-11-05
- Earliest claimed: 2005-06-17
- Assignees: Mount Sinai Hospital; The General Hospital Corporation; Board of Trustees of Michigan State University
- Inventors: Andrea Jurisicova; Robert Casper; Gloria I. Perez
- Web page: https://patentgrep.com/patent/US20090275502A1

## CPC

- A61K 38/17: from animals; from humans {(enzyme inhibitors A61K38/005)}
- C12N 5/0604: {Whole embryos; Culture medium therefor}
- C12N 2501/48: Regulators of apoptosis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention relates to compositions and methods for enhancing the developmental potential of oocytes or preimplantation embryos by modulating mitochondrial-associated proteins and/or genomic integrity modifier proteins in the oocytes or preimplantation embryos. In one aspect of the invention, the levels of one or more mitochondrial-associated proteins and/or genomic integrity modifier proteins are increased, in particular by introducing the mitochondrial-associated proteins and/or genomic integrity modifier proteins into the oocytes or preimplantation embryos. Oocytes may be fertilized to obtain a zygote with increased levels of one or more mitochondrial-associated proteins and/or genomic integrity modifier proteins. The methods and compositions may be used to improve in vitro fertilization and embryo transfer methods, and nuclear transfer techniques.

## Claims

### Claim 1

A method for enhancing developmental potential of oocytes or preimplantation embryos, improving the success of in vitro fertilization, improving the success of gamete intrafallopian transfer, or improving the success of zygote intrafallopian transfer, said method comprising modulating one or more mitochondrial-associated proteins, genomic integrity modifier proteins, or a combination thereof in the oocytes or preimplantation embryos.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

A method according to claim 1, wherein the levels of one or more mitochondrial-associated proteins, genomic integrity modifier proteins, or a combination thereof are increased by introducing the proteins into the oocytes or preimplantation embryos.

### Claim 4 (depends on 3)

A method according to claim 3 wherein the proteins are introduced by microinjection or electrofusion.

### Claim at position 5

5-6. (canceled)

### Claim 7 (depends on 1)

A method according to claim 1, further comprising fertilizing the oocyte to obtain a zygote with increased levels of mitochondrial-associated proteins, genomic integrity modifier proteins, or a combination thereof.

### Claim 8

A method for fertilizing oocytes, said method comprising removing oocytes from a follicle of an ovary, modulating one or more mitochondrial-associated proteins, genomic integrity modifier proteins, or a combination thereof, and fertilizing the resulting oocytes with spermatozoa.

### Claim 9 (depends on 8)

A method according to claim 8, wherein the mitochondrial-associated proteins, genomic integrity modifier proteins. or a combination thereof are introduced into the oocytes.

### Claim 10 (depends on 8)

A method of according to claim 8 wherein modulating the proteins and fertilizing the spermatozoa can be carried out simultaneously, sequentially, or separately.

### Claim 11

A method for improving embryo development after in vitro fertilization or embryo transfer in a female mammal comprising implanting into the female mammal an embryo derived from an oocyte or preimplantation embryo wherein one or more mitochondrial-associated proteins, genomic integrity modifier proteins, or a combination thereof have been modulated.

### Claim 12 (depends on 11)

A method according to claim 11, wherein the oocyte or preimplantation embryo comprises increased levels of one or more pro-survival Bcl-2 family proteins, and/or Rad51 family proteins, or a combination thereof.

### Claim 13

(canceled)

### Claim 14 (depends on 1)

A method according to claim 1 which is for improving the success of in vitro fertilization in a female subject and comprises:
(a) removing oocytes from the subject;
(b) modulating one or more mitochondrial-associated proteins, genomic integrity modifier proteins, or a combination thereof in the oocytes;
(c) fertilizing the oocytes with spermatozoa; and
(d) transferring fertilized oocytes from step (c) into the uterus of the subject.

### Claim 15

A method for enhancing developmental potential of recipient oocytes in a nuclear transfer method, said method for enhancing developmental potential of recipient oocytes comprising introducing one or more mitochondrial-associated proteins, and/or genomic integrity modifier proteins or a combination thereof into the recipient oocytes.

### Claim 16

(canceled)

### Claim 17 (depends on 15)

A method according to claim 15 wherein the mitochondrial-associated Bcl 2 family protein is a pro-survival Bcl-2 family protein.

### Claim 18 (depends on 17)

A method according to claim 17, wherein the pro-survival Bcl-2 family protein is Bcl-2, Bcl-xL, Mcl-1, Diva, or Aven.

### Claim 19 (depends on 1)

A method according to preceding claim 1, wherein the genomic integrity modifier protein is a RecA family protein or a Rad51 family protein.

### Claim 20

(canceled)

### Claim 21 (depends on 19)

A method according to claim 19, wherein the genomic integrity modifier protein is Rad51.

### Claim at position 21

22-27. (canceled)

### Claim 28

A composition for enhancing developmental potential of oocytes and preimplantation embryos, said composition comprising one or more mitochondrial-associated proteins genomic integrity modifier proteins, or a combination thereof and a pharmaceutically acceptable carrier, excipient or diluent.

### Claim 29

(canceled)

### Claim 30 (depends on 28)

A composition according to claim 28, wherein the mitochondrial-associated protein is a pro-survival Bcl-2 family protein.

### Claim 31 (depends on 28)

A composition according to any preceding claim 28, wherein the genomic integrity modifier protein is a RecA family protein or a Rad51 family protein.

### Claim 32

(canceled)

### Claim 33 (depends on 31)

A composition according to claim 31, wherein the genomic integrity modifier protein is Rad51.

### Claim 34 (depends on 1)

A kit for carrying out a method of claim 1.

### Claim 35

(canceled)
